- NCIt
- C3512
- OncoTree
- LUAD
- DOID
- 3910
- UMLS CUI
- C0152013
- MeSH
- D000077192
Loading cancer entity…
Loading cancer entity…
Clinical trials
231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (28)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | completed | Phase 1 | 65 | University of PennsylvaniaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) |
| completed |
| Phase 1 / Phase 2 |
| 25 |
| Shanghai Chest HospitalOTHER |
| 1 |
| Aug 15, 2024 |
| clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02120807 | Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas | completed | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02535325 | Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01958372 | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 11 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT01668823 | Photodynamic Therapy in Treating Patients With Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Sep 5, 2025source: clinicaltrials